CHNA Loncar China BioPharma ETF
Loncar China BioPharma TR USD

NAV as of 02-Dec-2022

17.8987

4 Week: 16.17 - 18.79

52 Week: 13.50 - 32.57

Latest Closing Price

17.78

Premium / Discount

0.57

Expense Ratio

0.79%

Investment Objective

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.

Main Fund Characteristics

Fund Manager:
Loncar Investments
Asset Under Management:
5,373,390
Launch Date:
13/08/2018
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
63
Trading Currency:
USD
Style:
Mid Blend
Region/Sector/Strategy:
China / N.A / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-33.573.30-10.16
1 Day-3.660.000.00
1 Week1.465.610.26
1 Month7.2117.100.42
3 Months-1.9030.62-0.06
6 Months-0.8135.76-0.02
1 Year-44.0853.42-0.83
2 Years-41.6662.50-0.67
3 Years-25.7969.66-0.37
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00000.00000.00000.00000.000030.663134.3839-9.4178
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.000045.000048.000050.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
28/12/202130/12/20213.0314
22/12/201925/12/20190.0403

Portfolio Data

Total Number of Holdings: 63

Number of Bond Holdings: 0

Number of Equity Holdings: 60

Total Market Value: 5,373,390

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1BeiGene Ltd ADR2.84967580153,010
2Keymed Biosciences Inc2.816624,0000151,240
33SBio Inc Shs Unitary 144A/Reg S2.8011144,0000150,408
4Akeso Inc Ordinary Shares2.764936,0000148,465
5CSPC Pharmaceutical Group Ltd2.7160124,8800145,839
6CanSino Biologics Inc Class H2.598412,0000139,523
7China Resources Pharmaceutical Group Ltd Registere2.5503165,0000136,941
8Sino Biopharmaceutical Ltd2.5192234,5000135,271
9Luye Pharma Group Ltd2.4407328,0000131,054

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant6.57
Large34.88
Medium34.73
Small18.35
Micro5.22

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

13.9185

Price/Book*

1.8272

Price/Sales*

1.0025

Price/Cash Flow*

11.1252

Dividend Yield*

1.1766

Growth Measures

Long-Term Earnings

14.1805

Historical Earnings

14.0807

Sales Growth

14.0292

Cash-Flow Growth

5.1208

Book-Value Growth

15.2030

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.